Final answer:
The key side effect to assess for in a patient receiving an IIb/IIIa inhibitor IV drip while being transferred is bleeding.
Step-by-step explanation:
The key side effect to assess for in a patient receiving an IIb/IIIa inhibitor IV drip while being transferred is bleeding. IIb/IIIa inhibitors such as Aggrastat, Integrilin, and Reopro are antiplatelet medications used to prevent blood clots. While they can be effective in preventing clotting, they can also increase the risk of bleeding.
It is important to monitor the patient closely for signs of bleeding, such as easy bruising, nosebleeds, or blood in the urine or stool.